Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar;159(5):1133-42.
doi: 10.1111/j.1476-5381.2009.00619.x. Epub 2010 Feb 5.

Vasodilator therapy with hydralazine induces angiotensin AT receptor-mediated cardiomyocyte growth in mice lacking guanylyl cyclase-A

Affiliations

Vasodilator therapy with hydralazine induces angiotensin AT receptor-mediated cardiomyocyte growth in mice lacking guanylyl cyclase-A

Y Li et al. Br J Pharmacol. 2010 Mar.

Abstract

Background and purpose: Recent clinical guidelines advocate the use of the isosorbide dinitrate/hydralazine combination in treatment for heart failure. However, clinical and laboratory evidence suggest that some vasodilators may induce cardiac hypertrophy under uncertain conditions. This study investigated the effects and underlying mechanism of action of the vasodilator hydralazine on cardiac growth.

Experimental approach: Wild-type mice and animals deficient in guanylyl cyclase-A (GCA) and/or angiotensin receptors (AT(1) and AT(2) subtypes) were treated with hydralazine ( approximately 24 mg.kg(-1).day(-1) in drinking water) for 5 weeks. Cardiac mass and/or cardiomyocyte cross-sectional area, fibrosis (van Giessen-staining) and cardiac gene expression (real-time RT-PCR) were measured.

Key results: Hydralazine lowered blood pressure in mice of all genotypes. However, this treatment increased the heart and left ventricular to body weight ratios, as well as cardiomyocyte cross-sectional area, and cardiac expression of atrial natriuretic peptide mRNA in mice lacking GCA. Hydralazine did not affect cardiac hypertrophy in wild-type mice and mice lacking either AT(1) or AT(2) receptors alone. However, the pro-hypertrophic effect of hydralazine was prevented in mice lacking both GCA and AT(2), but not GCA and AT(1) receptors. However, hydralazine did decrease cardiac collagen deposition and collagen I mRNA (signs of cardiac fibrosis) in mice that were deficient in GCA, or both GCA and AT(2) receptors.

Conclusions and implications: The vasodilator hydralazine induced AT(2) receptor-mediated cardiomyocyte growth under conditions of GCA deficiency. However, attenuation of cardiac fibrosis by hydralazine could be beneficial in the management of cardiac diseases.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Systolic blood pressure (SBP, A) and the ratios of heart weight to body weight (HW/BW, B) and left ventricular weight to body weight (LVW/BW, C) in wild-type (WT) and guanylyl cyclase-A-deficient [GCA knockout (KO) mice] mice. Hydralazine (HYD) was administered in drinking water (≈24 mg·kg−1·day−1) for 5 weeks, while the mice in control groups received drinking water only. SBP was measured in conscious mice prior to, and at weekly intervals after, the commencement of treatment using a computerized tail-cuff method. Hearts and left ventricles were weighed at the conclusion of the experiments (week 5), and HW/BW and LVW/BW were calculated. Values are means ± SEM (n = 7−14). *P < 0.05; $different from WT control (HYD −) or #different from GCA KO (HYD −) at corresponding time-points (P < 0.05). HYD −: control, without HYD; HYD +, with HYD.
Figure 2
Figure 2
Cardiomyocyte cross-sectional areas in wild-type (WT) and guanylyl cyclase-A (GCA) knockout (KO) mice. Hydralazine (HYD) was administered in drinking water (≈24 mg·kg−1·day−1) for 5 weeks, while the mice in control groups received drinking water only. Morphometry of left ventricular myocytes was performed to measure the myocyte cross-sectional area. Values are means ± SEM (n = 7−14). *P < 0.05. (A) Results of cardiomyocyte cross-sectional areas with or without HYD treatment. (B) Representative histological findings of cardiomyocytes in different experimental groups. Original magnification: ×400. HYD −: control, without HYD; HYD +, with HYD.
Figure 3
Figure 3
Cardiac fibrosis in wild-type (WT) and guanylyl cyclase-A (GCA) knockout (KO) mice. Hydralazine (HYD) was administered in drinking water (≈24 mg·kg−1·day−1) for 5 weeks, while the mice in control groups received drinking water only. After van Giessen-staining the area of collagen deposition in the interstitial region and the total left ventricular area were quantified using an image analysing system. (A) Interstitial fibrosis (%, the ratio of the area of interstitial collagen accumulation to the total left ventricular area); (B) Representative examples of interstitial fibrosis (red) (original magnification: ×200). Values are means ± SEM (n = 7–14). *P < 0.05. HYD −: control, without HYD; HYD +, with HYD.
Figure 4
Figure 4
Left ventricular expression of mRNA for atrial natriuretic peptide (ANP, A) or collagen I (B) in wild-type (WT) and guanylyl cyclase-A (GCA) knockout (KO) mice. Hydralazine (HYD) was administered in drinking water (≈24 mg·kg−1·day−1) for 5 weeks, while the mice in control groups received drinking water only. Total RNA was extracted from the left ventricular tissues using TRIzol. The relative levels of specific mRNAs were assessed by real-time RT-PCR. Results were normalized to GAPDH. Levels in WT group were arbitrarily assigned a value of 1. Values are means ± SEM (n = 7). *P < 0.05. HYD −: control, without HYD; HYD +, with HYD.
Figure 5
Figure 5
Systolic blood pressure (SBP, A), the ratios of heart weight to body weight (HW/BW, B) and left ventricular weight to body weight (LVW/BW, C) and cardiac interstitial fibrosis (D) in angiotensin II type 1 (AT1) receptor knockout (KO) and guanylyl cyclase-A (GCA)/AT1 double KO (DKO) mice. Hydralazine (HYD) was administered in drinking water (≈24 mg·kg−1·day−1) for 5 weeks, while the mice in control groups received drinking water only. SBP was measured in conscious mice prior to, and at weekly intervals after, the commencement of treatment using a computerized tail-cuff method. Hearts and left ventricles were weighed at the conclusion of the experiments (week 5), and HW/BW and LVW/BW were calculated. After van Giessen-staining the area of collagen deposition on the interstitial region and the total left ventricular area were quantified using an image analysing system. Values are means ± SEM (n = 6−7). *P < 0.05; $different from AT1 KO (HYD −), or #different from GCA/AT1 DKO (HYD −) at corresponding time-points (P < 0.05). HYD −: control, without HYD; HYD +, with HYD.
Figure 6
Figure 6
Left ventricular expression of mRNA for atrial natriuretic peptide (ANP, A) and collagen I (B) in angiotensin II type 1 (AT1) receptor knockout (KO) and guanylyl cyclase-A (GCA)/AT1 double KO (DKO) mice. Hydralazine (HYD) was administered in drinking water (≈24 mg·kg−1·day−1) for 5 weeks, while the mice in control groups received drinking water only. Total RNA was extracted from the left ventricular tissues using TRIzol. The relative levels of specific mRNAs were assessed by real-time RT-PCR. Results were normalized to GAPDH. Levels in WT group were arbitrarily assigned a value of 1. Values are means ± SEM (n = 6−7). *P < 0.05. HYD −: control, without HYD; HYD +, with HYD.
Figure 8
Figure 8
Left ventricular expression of mRNA for atrial natriuretic peptide (ANP, A) and collagen I (B) in angiotensin II type 2 (AT2) receptor and in guanylyl cyclase-A (GCA) and AT2 double knockout (DKO) mice. Hydralazine (HYD) was administered in drinking water (≈24 mg·kg−1·day−1) for 5 weeks, while the mice in control groups received drinking water only. Total RNA was extracted from the left ventricular tissues using TRIzol. The relative levels of specific mRNAs were assessed by real-time RT-PCR. Results were normalized to GAPDH. Levels in wild-type group were arbitrarily assigned a value of 1. Values are means ± SEM (n = 7–8). *P < 0.05. HYD −: control, without HYD; HYD +, with HYD.
Figure 7
Figure 7
Systolic blood pressure (SBP, A), the ratios of heart weight to body weight (HW/BW, B) and left ventricular weight to body weight (LVW/BW, C) and cardiac interstitial fibrosis (D) in angiotensin II type 2 (AT2) receptor knockout (KO) and guanylyl cyclase-A (GCA)/AT2 double KO (DKO) mice. Hydralazine (HYD) was administered in drinking water (≈24 mg·kg−1·day−1) for 5 weeks, while the mice in control groups received drinking water only. SBP was measured in conscious mice prior to, and at weekly intervals after, the commencement of treatment using a computerized tail-cuff method. Hearts and left ventricles were weighed at the conclusion of the experiments (week 5), and HW/BW and LVW/BW were calculated. After van Giessen-staining the area of collagen deposition on the interstitial region and the total left ventricular area were quantified using an image analysing system. Values are means ± SEM (n = 7–8). *P < 0.05; $different from AT2 KO (HYD −), or #different from GCA/AT2 DKO (HYD −) at corresponding time-points (P < 0.05). HYD −: control, without HYD; HYD +, with HYD.

Similar articles

Cited by

References

    1. Bauer JA, Fung HL. Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation. 1991;84:35–39. - PubMed
    1. Bhatnagar RS, Rapaka SSR, Liu TZ, Wolfe SM. Hydralazine-induced disturbances in collagen biosynthesis. Biochim Biophys Acta. 1972;271:125–132. - PubMed
    1. D'Amore A, Black MJ, Thomas WG. The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. Hypertension. 2005;46:1347–1354. - PubMed
    1. Fenje P, Leenen FH. Effects of minoxidil on blood pressure and cardiac hypertrophy in two-kidney, one-clip hypertensive rats. Can J Physiol Pharmacol. 1985;63:161–164. - PubMed
    1. Gerber JG, Nies AS. Ahtihypertensive agents and the drug therapy of hypertension. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. The Pharmacological Basis of Therapeutics. New York: Pergamon Press; 1990. pp. 784–813.

Publication types

MeSH terms

Substances